4+1 the right balance in Parkinson's disease

Madopar
the original 4+1 combination in three dosage forms, 62.5, 125 and 250
A new era in the treatment of Parkinson's disease begins...

In 1970, the arrival of L-dopa revolutionised the treatment of Parkinson's disease. This was followed, in 1973 and 1979, by the highly successful combinations with peripheral decarboxylase inhibitors.

Now, in 1983, there is Eldepryl

Eldepryl is a new, selective inhibitor of the enzyme responsible for dopamine breakdown in the brain. Used in conjunction with L-dopa preparations, it provides the next logical step in treatment – dopamine conservation.

The patient benefits of Eldepryl are substantial – Daily L-dopa intake can be immediately cut by 20% in most cases, reducing unwanted side effects and extending the useful life of L-dopa. Eldepryl significantly reduces akinesia, and has been shown to smooth out “on-off” effects.

With Eldepryl, there is no complicated dosage regime to remember, simply one tablet daily, together with a 20% reduction of L-dopa on the first day of treatment, is usually all that is required.

---

**PREScribing information**

Presentation: White, scored, uncoated tablets 6 mm diameter containing 5 mg selegiline hydrochloride. Indications: Eldepryl is indicated for the treatment of Parkinson's disease, or symptomatic Parkinsonism which is being treated with levodopa alone or levodopa and a peripheral decarboxylase inhibitor. Eldepryl in conjunction with levodopa treatment is particularly indicated in patients who, during maximal levodopa treatment, developed on-off symptoms or other dyskinesia. Dosage: When given in conjunction with established levodopa therapy, the initial dose of Eldepryl is 5 mg (1 tablet) in the morning. If symptoms are very severe e.g. on-off symptoms, and little response is achieved with 1 tablet Eldepryl daily, the dose of Eldepryl can be increased to 10 mg (2 tablets) in the morning. Contra-indications: There are no known contra-indications for the use of Eldepryl in patients receiving levodopa therapy. Warnings: Because Eldepryl potentiates the effects of levodopa, the side effects of levodopa might be emphasized. When Eldepryl is added, it is recommended that levodopa dosage be reduced. When Eldepryl is added, levodopa treatment should be reduced by an average of 30%.

---


Further information is available on request from Britannia Pharmaceuticals Limited, Lonsdale House, 7-11 High Street, Reigate, Surrey RH2 9RR.
Tegretol®
carbamazepine BP

making epilepsy
easier to live with

Tegretol®

Indications: Epilepsy (grand mal and temporal lobe), trigeminal neuralgia. Dosage in epilepsy: Use a gradually increasing dosage scheme, adjusting to patient's needs. Adult: 100-200mg once or twice daily, increasing slowly to 800-1200mg daily, in some cases 1600mg daily may be necessary. Children: up to 1 year old, 100-200mg daily; aged 1-5 years, 200-400mg daily; aged 5-10 years, 400-600mg daily; aged 10-15 years, 600-1000mg daily. It may be helpful to monitor plasma drug levels. Optimum therapeutic range is 3-10 µg/mL (13-40 nmol/L). Dosage in trigeminal neuralgia: Begin with small doses, using 100mg tablets or syrup, and increase gradually until satisfactory therapeutic response is obtained. 200mg 3-4 times daily is generally sufficient to maintain pain-free state. Side-effects: Dizziness and diplopia (usually dose-dependent), less frequently dryness of mouth, drowsiness, nausea and vomiting. Generalised erythematous rash: Disappearing on cessation of therapy. Isolated reports of oedema hypocalcaemia, exfoliative dermatitis, leukopenia, thrombocytopenia, agranulocytosis. aplastic anaemia, cholestatic jaundice and acute renal failure. Blood count should be checked in early stages of treatment. Precautions: Caution in patients taking oral anticoagulants or requiring oral contraception. In pregnancy, potential benefits of Tegretol must be weighed against potential hazards. Do not administer with or within two weeks of cessation of MAOI therapy. In rats treated with carbamazepine for two years, incidence of liver tumours increased (no evidence of significant bearing on the therapeutic use of the drug). Serum folate levels should be observed during anticonvulsant therapy. Contra-indications: Previous drug sensitivity to Tegretol. Do not administer to patients with sinoatrial node disturbances unless paced. Packets: Tablets of 100mg (PL0001 5000T) basic NHS price £2.99 per 100, £14.40 per 500 tablets of 200mg (PL0001 5020T) £5.56 per 100, £26.78 per 500. syrup: 100mg/5ml (PL0001 0088) £10.92 per 100, syrup 160mg/5ml (PL0001 0050) £5.34 per 300ml bottle. Full prescribing information is available on request from Geigy Pharmaceuticals, Horsham, West Sussex.
Schizophrenia, Depression, Anxiety; Alzheimer's, Parkinson's, Huntington's Diseases; Epilepsy; Pain - all areas where basic knowledge has advanced greatly over the past decade.

NEUROTRANSMITTERS AND CNS DISEASE

is now available as a LANCET page-size combined reprint, with index.

The reprint costs £2.25 Orders with prepayment should be sent to:

THE LANCET

Publications Department, (JN) 7 Adam Street, London WC2N 6AD
Journal of Mental Deficiency Research

Published on behalf of the Royal Society for Mentally Handicapped Children and Adults

In 1982, Journal of Mental Deficiency Research celebrated its twenty-fifth anniversary. These years have seen remarkable developments: identification of Down's anomaly; behavioural techniques; screening methods; infant intervention programmes; normalization philosophy and community care; errorless learning; verbal and non-verbal communication approaches; amniocentesis; the sex chromosome disorders; the Fragile X chromosome disorders; secondary prevention; demographic changes; and enlightenment.

The pace of change in the next twenty-five years will increase. This journal will continue to evaluate and record important medical, social and educational advances.

Manuscripts for publication should be submitted to the Editor, Dr W.I. Fraser, Blackwell Scientific Publications Ltd, 8 John Street, London WC1N 2ES, England.

Subscription Information
Journal of Mental Deficiency Research is published quarterly.
Subscription rates for 1983 are:
£25.00 (U.K.)
£30.00 (overseas)
$62.50 (U.S.A. & Canada) post free

Order Form
Send to Blackwell Scientific Publications Ltd., P.O. Box 88, Oxford, England

Please tick the appropriate box

☐ I would like to subscribe to Journal of Mental Deficiency Research and I enclose my remittance for the current volume

☐ I would like a free specimen copy of Journal of Mental Deficiency Research

Name ..........................................................

Address ........................................................

........................................................................

Blackwell Scientific Publications
Oxford · London · Edinburgh · Boston · Melbourne

Published by British Medical Association, Tavistock Square, London WC1H 9JR
and printed in England by Eyre & Spottiswoode Ltd, Thanet Press, Margate